Dimensional Fund Advisors LP Raises Stake in Johnson & Johnson (JNJ)
Dimensional Fund Advisors LP raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,417,794 shares of the company’s stock after buying an additional 280,008 shares during the period. Johnson & Johnson makes up approximately 0.4% of Dimensional Fund Advisors LP’s holdings, making the stock its 20th largest position. Dimensional Fund Advisors LP’s holdings in Johnson & Johnson were worth $739,409,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in JNJ. Itau Unibanco Holding S.A. purchased a new stake in shares of Johnson & Johnson during the third quarter valued at $104,000. Hefty Wealth Partners boosted its stake in shares of Johnson & Johnson by 559.4% in the third quarter. Hefty Wealth Partners now owns 1,121 shares of the company’s stock valued at $132,000 after buying an additional 951 shares during the last quarter. Wechter Feldman Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $209,000. New Capital Management LP purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $214,000. Finally, Turner Investments LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $218,000. Institutional investors own 65.30% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 128.07 on Tuesday. Johnson & Johnson has a 52-week low of $106.36 and a 52-week high of $129.00. The company’s 50 day moving average price is $119.96 and its 200 day moving average price is $117.07. The stock has a market capitalization of $347.50 billion, a PE ratio of 21.59 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.56 by $0.02. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The firm had revenue of $18.10 billion for the quarter, compared to the consensus estimate of $18.28 billion. During the same period in the previous year, the business earned $1.44 EPS. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post $7.04 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 14th. Investors of record on Tuesday, February 28th were paid a dividend of $0.80 per share. The ex-dividend date was Friday, February 24th. This represents a $3.20 annualized dividend and a yield of 2.50%. Johnson & Johnson’s dividend payout ratio (DPR) is 54.42%.
Your IP Address:
Several brokerages recently weighed in on JNJ. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, January 3rd. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $124.53 price target on the stock. in a research note on Thursday, February 23rd. Goldman Sachs Group Inc reduced their price target on Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 25th. Wells Fargo & Co cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $112.28 to $112.80 in a research note on Thursday, January 26th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $107.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 20th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $124.09.
In related news, VP Paulus Stoffels sold 22,000 shares of the business’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total transaction of $2,580,380.00. Following the transaction, the vice president now directly owns 127,650 shares in the company, valued at approximately $14,972,068.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.11% of the stock is owned by insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.